Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL198437 | 0.86 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL30838382 | 0.86 | MEN1 (0.47) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4819525 | 0.84 | MEN1 (0.61) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4070919 | 0.83 | KDM4E (0.57) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL23147126 | 0.83 | KMT2A (0.60) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL29843374 | 0.82 | MAPK1 (0.50) | MEN1KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL14044509 | 0.82 | MEN1 (0.58) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL4815404 | 0.82 | MEN1 (0.58) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL21777459 | 0.81 | MEN1 (0.57) | MEN1KMT2AALDH1A1KDM4EHSD17B10 | |
| SCHEMBL21777894 | 0.80 | MEN1 (0.56) | MEN1KMT2AALDH1A1KDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371428-B2 | Pyridone compounds and methods of use | EXELIXIS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4573085-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | Glenmark Pharmaceuticals Limited (IN) | 2025-06-25 | — | — | EP | disclosed |
| CN-119546587-A | Substituted pyridone compounds as CBL-B inhibitors | 格兰玛克制药有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC. (US) | 2024-05-30 | — | — | US | disclosed |
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-20240150325-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | LG CHEM, LTD. (KR) | 2024-05-09 | — | — | US | disclosed |
| WO-2024038378-A1 | SUBSTITUTED PYRIDINONE COMPOUNDS AS CBL-B INHIBITORS | GLENMARK PHARMACEUTICALS LTD (IN) | 2024-02-22 | — | — | WO | disclosed |
| EP-3843850-B1 | PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | ARRAY BIOPHARMA INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-4273140-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | Lg Chem, Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273140-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR | Lg Chem, Ltd. (KR) | 2023-11-08 | — | — | EP | disclosed |
| WO-2019182274-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7439246-B2 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-10-21 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-09-21 | — | — | US | disclosed |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-01-05 | — | — | US | disclosed |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150325-A1 | NOVEL COMPOUND AS PROTEIN KINASE INHIBITORS | MAP3K20, SBK3, MAPKAPK2 | MEN1 2933/4885KMT2A 2167/4885ALDH1A1 4608/4885 |
| US-20050288290-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MEN1 1216/4885KMT2A 953/4885ALDH1A1 3087/4885 |
| US-12371428-B2 | Pyridone compounds and methods of use | PDXK, PLK2, MAP4K2 | MEN1 3040/4885KMT2A 3773/4885ALDH1A1 4282/4885 |
| US-20060004006-A1 | Pyrrolotriazine kinase inhibitors | MAP3K5, MAP3K15, MAP4K2 | MEN1 2112/4885KMT2A 785/4885ALDH1A1 3818/4885 |
| US-20240174666-A1 | PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS INHIBITORS OF TAM AND MET KINASES | RET, MERTK, MET | MEN1 420/4885KMT2A 1340/4885ALDH1A1 2323/4885 |
| US-20060211695-A1 | Fused heterocyclic kinase inhibitors | MAP3K20, MAP3K19, ABL1 | MEN1 1216/4885KMT2A 953/4885ALDH1A1 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.